Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Lett. 2009 Jul 18;280(1):1-14. doi: 10.1016/j.canlet.2008.10.045. Epub 2008 Dec 18.

MET receptor tyrosine kinase as a therapeutic anticancer target.

Author information

  • 1Department of Experimental Therapeutics, Unit 71, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. cmstellre@mdanderson.org

Abstract

Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth, progression, metastasis, and therapeutic resistance. Because MET is a player in so many aspects of cancer development and progression, it is a strong candidate for targeted therapy. Numerous agents have been developed that are able to target MET expression and/or function and are the focus of this review.

PMID:
19100682
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk